Compare · SNN vs ZY
SNN vs ZY
Side-by-side comparison of Smith & Nephew SNATS Inc. (SNN) and Zymergen Inc. (ZY): market cap, price performance, sector, and recent activity on the wire.
Summary
- SNN operates in Health Care, while ZY operates in Industrials - the two are in different parts of the market.
- SNN is the larger of the two at $13.41B, about 27.5x ZY ($488.5M).
- SNN has hit the wire 6 times in the past 4 weeks while ZY has been quiet.
- SNN has more recent analyst coverage (22 ratings vs 13 for ZY).
- Company
- Smith & Nephew SNATS Inc.
- Zymergen Inc.
- Price
- $31.57-1.16%
- $2.44+2.10%
- Market cap
- $13.41B
- $488.5M
- 1M return
- -2.70%
- -
- 1Y return
- +18.02%
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 6
- 0
- Recent ratings
- 22
- 13
Smith & Nephew SNATS Inc.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
Zymergen Inc.
Zymergen Inc. designs, engineers, and optimizes microbes for industrial applications in United States, Asia, and Europe. The company has a platform that treats the genome as a search space, to identify genetic changes that improve the economics for its customers' bio-based products for a range of industries, including chemicals and materials, agriculture, and pharmaceuticals. Zymergen's platform is used to discover novel molecules used to enable unique material properties. The company was incorporated in 2013 and is based in Emeryville, California.
Latest SNN
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- New data for Smith+Nephew's CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant demonstrates superior pain relief and functional gains at 5-years
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- Amendment: SEC Form 6-K/A filed by Smith & Nephew SNATS Inc.
- Smith+Nephew's REGENETEN◊ Bioinductive Implant shows post-operative recovery times halved, and high healing rates for partial-thickness rotator cuff tears1,*
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
Latest ZY
- SEC Form 15-12G filed by Zymergen Inc.
- SEC Form EFFECT filed by Zymergen Inc.
- SEC Form SC 13G/A filed by Zymergen Inc. (Amendment)
- SEC Form 4: Svf Excalibur (Cayman) Ltd disposed of 26,614,219 shares
- SEC Form 4: Flatley Jay T returned 144,789 shares to the company, closing all direct ownership in the company
- SEC Form 4: Chu Steven returned 50,000 shares to the company, closing all direct ownership in the company
- SEC Form 4: Peterson Sandra E returned 119,119 shares to the company, closing all direct ownership in the company
- SEC Form 4: Murdoch Travis returned 79,697 shares to the company, closing all direct ownership in the company
- SEC Form 4: Gorjanc Christine Marie returned 50,000 shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Sharma Rohit